Retrieve available abstracts of 27 articles: HTML format
Single Articles
April 2025
FRANCA VELO A, Giantini Larsen A, Humm JL, Zanzonico P, et al Determination of the Intralesional Distribution of Theranostic (124)I-Omburtamab
Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.
J Nucl Med. 2025 Apr 30:jnumed.124.267995. doi: 10.2967/jnumed.124.267995. PubMedAbstract available
BARRY N, Kendrick J, Rowshanfarzad P, Hassan GM, et al An External, Independent Validation of an O-(2-[(18)F]Fluoroethyl)-l-Tyrosine PET
Automatic Segmentation Network on a Single-Center, Prospective Dataset of
Patients with Glioblastoma.
J Nucl Med. 2025 Apr 3:jnumed.124.268925. doi: 10.2967/jnumed.124.268925. PubMedAbstract available
March 2025
IMBER BS, Yu KKH, Abida W, Pike LRG, et al Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After
Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617.
J Nucl Med. 2025 Mar 6:jnumed.124.269175. doi: 10.2967/jnumed.124.269175. PubMed
January 2025
LANGEN KJ, Stoffels G, Filss CP, Kocher M, et al Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with
Suspected Glioma Relapse: Role in Clinical Practice.
J Nucl Med. 2025 Jan 16:jnumed.124.268768. doi: 10.2967/jnumed.124.268768. PubMedAbstract available
November 2024
ERMIS E, Bachmann N, Lutz K, Pyka T, et al Meningioma Revisited: Should Whole-Body Staging with [(68)Ga]Ga-DOTATOC PET/CT of
High-Grade Meningiomas Become Standard Practice?
J Nucl Med. 2024 Nov 21:jnumed.124.267934. doi: 10.2967/jnumed.124.267934. PubMed
October 2024
AMEREIN A, Maurer C, Kircher M, Gable A, et al Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients
with Advanced Meningioma: Initial Safety and Efficacy.
J Nucl Med. 2024 Oct 24:jnumed.124.268217. doi: 10.2967/jnumed.124.268217. PubMedAbstract available
ALBERT NL, Preusser M, Galldiks N, Ivanidze J, et al Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave
the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor
Ligands.
J Nucl Med. 2024 Oct 10:jnumed.124.268314. doi: 10.2967/jnumed.124.268314. PubMed
August 2024
PANDIT-TASKAR N, Zanzonico PB, Grkovski M, Donzelli M, et al Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in
Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion
Dosimetry.
J Nucl Med. 2024 Aug 14:jnumed.123.266365. doi: 10.2967/jnumed.123.266365. PubMedAbstract available
SEVERI S, Grassi I, Bongiovanni A, Nicolini S, et al Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas:
Efficacy and Toxicity in a Long Follow-up.
J Nucl Med. 2024 Aug 14:jnumed.123.266956. doi: 10.2967/jnumed.123.266956. PubMedAbstract available
July 2024
WICHMANN CW, Morgan KA, Cao Z, Osellame LD, et al Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of (225)Ac-ch806
in Glioblastoma and Colorectal Cancer Xenograft Models.
J Nucl Med. 2024 Jul 25:jnumed.123.266894. doi: 10.2967/jnumed.123.266894. PubMedAbstract available
OSTER C, Kessler L, Blau T, Keyvani K, et al The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A
Comparison of Tissue, (68)Ga-FAPI-46 PET Data, and Survival Data.
J Nucl Med. 2024 Jul 3:jnumed.123.267151. doi: 10.2967/jnumed.123.267151. PubMedAbstract available
April 2024
ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain
Metastases: A Cost-Effectiveness Analysis.
J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687. PubMedAbstract available
March 2024
PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional
Pituitary Tumors.
J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853. PubMedAbstract available
February 2024
EIGLER C, McDougall L, Bauman A, Bernhardt P, et al Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor
Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE
Phase 0 Study.
J Nucl Med. 2024 Feb 29:jnumed.123.266817. doi: 10.2967/jnumed.123.266817. PubMedAbstract available
LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al Example of Artificial Intelligence-Based Decision Support for Amino Acid PET:
Early Prediction of Suspected Brain Tumor Foci for Patient Management.
J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112. PubMed
TOLBOOM N, Verger A, Albert NL, Fraioli F, et al Theranostics in Neurooncology: Heading Toward New Horizons.
J Nucl Med. 2024;65:167-173. PubMedAbstract available
October 2023
MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying
Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868. PubMedAbstract available
September 2023
HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission
and Detecting Recurrence.
J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446. PubMed
August 2023
LOHMEIER J, Radbruch H, Brenner W, Hamm B, et al Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic
Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma
Using (18)F-FET PET.
J Nucl Med. 2023 Aug 31:jnumed.123.265642. doi: 10.2967/jnumed.123.265642. PubMedAbstract available
VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in
Glioblastoma: A Multicenter Inventory Study.
J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738. PubMedAbstract available
GUTSCHE R, Lowis C, Ziemons K, Kocher M, et al Automated Brain Tumor Detection and Segmentation for Treatment Response
Assessment Using Amino Acid PET.
J Nucl Med. 2023 Aug 10:jnumed.123.265725. doi: 10.2967/jnumed.123.265725. PubMedAbstract available
ALBERT NL, Nelwan DV, Fleischmann DF, Quach S, et al Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type
Glioblastoma.
J Nucl Med. 2023 Aug 3:jnumed.122.265247. doi: 10.2967/jnumed.122.265247. PubMedAbstract available
June 2023
MILOSEVIC A, Styczen H, Grueneisen J, Li Y, et al Evaluation of [(68)Ga]-DOTATOC PET/MRI in Patients with Meningioma of the
Subcranial and Intraorbital Space.
J Nucl Med. 2023 Jun 29:jnumed.123.265424. doi: 10.2967/jnumed.123.265424. PubMedAbstract available
May 2023
GALLDIKS N, Langen KJ Hybrid (18)F-FET PET and Perfusion MRI to Differentiate Disease Progression from
Treatment-Related Changes in Malignant Brain Tumors.
J Nucl Med. 2023 May 18:265647. doi: 10.2967/jnumed.123.265647. PubMed
April 2023
GRAEF J, Bluemel S, Brenner W, Amthauer H, et al [(177)Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with
High-Grade Glioma: Dosimetry Results and Critical Statement.
J Nucl Med. 2023 Apr 28:jnumed.122.264850. doi: 10.2967/jnumed.122.264850. PubMedAbstract available
SMITH NJ, Deaton TK, Territo W, Graner B, et al Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish
Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The
Quest to Beat the Toughest Cases.
J Nucl Med. 2023 Apr 28:jnumed.122.265149. doi: 10.2967/jnumed.122.265149. PubMedAbstract available
GALLDIKS N, Lohmann P, Fink GR, Langen KJ, et al Amino Acid PET in Neurooncology.
J Nucl Med. 2023 Apr 13:264859. doi: 10.2967/jnumed.122.264859. PubMedAbstract available